Alex Paynter

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial

Margaret Kloster, Steven Mark Rowe, David P. Nichols, Michael S. Stalvey et autres

Rationale: The cystic fibrosis (CF) modulator drug, elexacaftor/tezacaftor/ivacaftor (ETI), proved highly effective in controlled clinical trials for individuals with at least one F508del allele, which occurs in at least 85% of people with CF. Objectives: PROMISE is a postapproval study to understand …

us (code pays fourni par la source)

HLA Class I Amino Acid Mismatches That Distinguish Divergent HLA-A Allele Lineages Confer Incremental Risk of Kidney Allograft Failure Independent of Class II Mismatches

Keith P. McCullough, L. Gragert, Nicholas K. Brown, Ryan J. Urbanowicz et autres

us (code pays fourni par la source)

A Novel Machine Learning Algorithm Discovers Mismatched HLA Class I Amino Acid Positions That Confer Incremental Kidney Graft Failure Risk Independent of HLA Class II

Malek Kamoun, Harsh Bandhey, Keith P. McCullough, Nicholas K. Brown et autres

us (code pays fourni par la source)

Stepwise Models Identify Risk of Kidney Allograft Failure Associated with HLA Amino Acid Mismatches Among Adult FSGS Recipients

K. McCullough, L. Gragert, Nicholas K. Brown, Ryan J. Urbanowicz et autres

us (code pays fourni par la source)

Abstract 1118: The GENIE BPC BRCA Cohort: a real-world repository of standardized clinical and genomic data for young patients with breast cancer

Evan Seffar, Brooke Mastrogiacomo, Alex Paynter, Protiva Rahman et autres

Abstract Purpose: The first comprehensive analysis of the detailed clinico-genomic landscape of the breast cancer (BC) cohort of the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC). Methods: We analyzed 1, 045 BC patients …

us, ca (code pays fourni par la source)

DNA damage repair alterations as predictive biomarker for platinum-based chemotherapy in metastatic urothelial cancer.

Michal Sternschuss, Alex Paynter, Wenxin Vincent Xu, Chelsea Nichols et autres

853 Background: DNA damage repair gene alterations (DDRa), especially ERCC2 mutations, have been associated with improved clinical outcomes in patients with urothelial cancer (UC) treated with cisplatin-based neoadjuvant chemotherapy. The predictive value of DDR alterations for platinum-based chemotherapy in metastatic disease is …

us, ca (code pays fourni par la source)

Impact of day-to-day variation in FEV1 on measures of change: A conceptual description

Amalia Magaret, Ellen Graham, Lindsay J. Caverly, Elizabeth A. Cromwell et autres

us, ca (code pays fourni par la source)

WS06.02 How accurate is home spirometry? Comparison of home to office spirometry in the PROMISE study

Margaret Rosenfeld, Alex Paynter, P. Vu, Ashley‐Marie Cortes et autres

us, ca (code pays fourni par la source)

A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis

Alex Paynter, Umer Zaryab Khan, Sonya L. Heltshe, Christopher Hooper Goss et autres

us (code pays fourni par la source)

Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation

Jennifer S. Guimbellot, Arthur Baines, Alex Paynter, Sonya L. Heltshe et autres

us (code pays fourni par la source)

Tuning parameter selection for a penalized estimator of species richness

Alex Paynter, Amy D. Willis

Our goal is to estimate the true number of classes in a population, called the species richness. We consider the case where multiple frequency count tables have been collected from a homogeneous population, and investigate a penalized maximum likelihood estimator under a …

us (code pays fourni par la source)